TopDollar Investing

[Slimer84]

Leading Independent Laboratory Confirms Efficacy of BioNeutral's Ygiene? Antimicrobial
MicroChem Laboratory Inc. Tests Show Ygiene™ Rapidly Eliminates Tuberculosis

Nov. 23, 2010 (PR Newswire) --

NEWARK, N.J., Nov. 23, 2010 /PRNewswire/ -- BioNeutral Group (OTC Bulletin Board: BONU), a specialty technology-based life science company, today announced it has received independent laboratory results from MicroChem Laboratory Inc. indicating that Ygiene™ Hospital Grade antimicrobial eliminated tuberculosis in under five minutes. Dr. Norman Miner, owner and operator of MicroChem Laboratories was retained by H. Paul Dorman CEO of DFB Pharmaceuticals, to conduct an independent Standard Rate of Kill Tests of BioNeutrals Ygiene™ against tuberculosis. As previously announced, BioNeutral Group recently signed a "stand still" agreement with DFB Pharmaceuticals.

"Tuberculosis is often a deadly disease with over a quarter of the world's population suffering from some form of this disease," said Dr. Andrew Kielbania, Chief Scientist at BioNeutral Group. "With new infectious outbreaks occurring very rapidly, we believe there is a serious need for a highly effective new antimicrobial that can quickly eliminate this dangerous microorganism. These independent results from Dr. Miner's laboratory provide us additional support that our Ygiene™ Hospital Grade Antimicrobial is an exceptional product that can be used in the proactive preventative control and of this potentially very deadly disease.

About MicroChem Laboratory Inc.

MicroChem Laboratory is a contract laboratory established in 1988 to test liquid chemical germicides. They test sanitizers, general-, broad spectrum-, hospital grade-, and high-level disinfectants, sterilants, and other antimicrobial products. They also validate swimming pool disinfectants and algaecides.

MicroChem Laboratory is owned and operated by Dr. Norman Miner. Dr. Miner was instrumental in creating an AOAC Task Force with the goal of improving the chapter 6 AOAC Disinfectant Test Methods. Dr. Miner provides disinfectant and antimicrobial test method consulting services and is also available as an expert witness regarding disinfectants and disinfectant test methods.

The scientists at MicroChem Laboratory produce reader-friendly, crystal clear, quality assurance audited final study reports promptly after a study is completed. MicroChem Laboratory also conducts original research and publishes regularly in peer-reviewed journals regarding disinfectants and disinfectant test methods.

Member: AOAC, ASM, and ASTM.

For additional information see www.microchemlab.net

About DFB Pharmaceuticals:

DFB Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company whose operating subsidiaries and affiliates provide branded products, quality services and innovative technologies to the global healthcare industry. Its DPT Laboratories organization is the premier contract manufacturer of pharmaceutical grade liquid and semi-solid products and works with most of the leading pharmaceutical companies. OPT has FDA compliant manufacturing facilities in New Jersey and Texas. Through its affiliate Phyton Biotech GmbH, they also have manufacturing facilities in Germany where they produce a leading oncology API through an award winning environmentally friendly process. Its HealthPoint division alone employs approximately 250 individuals, including a sophisticated field sales force of approximately 150 individuals calling on the U.S. hospital market. The Company enjoys an excellent reputation as a leader in the wound care field. DFB Pharma has developed a number of novel technologies in the area of infection prevention, including the world's first brush-free surgeon's scrub.

For more information on DFB Pharmaceuticals Inc., see www.dfb.com

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. For more information, see www.bioneutralgroup.com or read our blog at www.bioneutralblog.com. AutoNeutral is a registered trademark of BioNeutral Group, Inc.

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

Media Contact:
Investor Relations:
Matt Rizzetta
Brett Maas
North 6th Agency
Hayden IR
917-398-0818
646-536-7331
[e-mail]
[e-mail]


For The Company:

BioNeutral Group, Inc.

Stephen J. Browand, President and CEO

973-286-2899

[e-mail]



SOURCE BioNeutral Group, Inc.


Source: PR Newswire (November 23, 2010 - 7:00 AM EST)

News by QuoteMedia
www.quotemedia.com